Sonazoid-enhanced ultrasonography for noninvasive imaging diagnosis of hepatocellular carcinoma: special emphasis on the 2022 KLCA-NCC guideline.

IF 2.4 3区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Ultrasonography Pub Date : 2023-10-01 Epub Date: 2023-06-15 DOI:10.14366/usg.23051

Hyo-Jin Kang, Jeong Min Lee, Se Woo Kim

{"title":"Sonazoid-enhanced ultrasonography for noninvasive imaging diagnosis of hepatocellular carcinoma: special emphasis on the 2022 KLCA-NCC guideline.","authors":"Hyo-Jin Kang, Jeong Min Lee, Se Woo Kim","doi":"10.14366/usg.23051","DOIUrl":null,"url":null,"abstract":"<p><p>Contrast-enhanced ultrasonography (CEUS) is a noninvasive imaging modality used to diagnose hepatocellular carcinoma (HCC) based on specific imaging features, without the need for pathologic confirmation. Two types of ultrasound contrast agents are commercially available: pure intravascular agents (such as SonoVue) and Kupffer agents (such as Sonazoid). Major guidelines recognize CEUS as a reliable imaging method for HCC diagnosis, although they differ depending on the contrast agents used. The Korean Liver Cancer Association-National Cancer Center guideline includes CEUS with either SonoVue or Sonazoid as a second-line diagnostic technique. However, Sonazoid-enhanced ultrasound is associated with several unresolved issues. This review provides a comparative overview of these contrast agents regarding pharmacokinetic features, examination protocols, diagnostic criteria for HCC, and potential applications in the HCC diagnostic algorithm.</p>","PeriodicalId":54227,"journal":{"name":"Ultrasonography","volume":" ","pages":"479-489"},"PeriodicalIF":2.4000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cd/69/usg-23051.PMC10555687.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ultrasonography","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14366/usg.23051","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 1

Abstract

Contrast-enhanced ultrasonography (CEUS) is a noninvasive imaging modality used to diagnose hepatocellular carcinoma (HCC) based on specific imaging features, without the need for pathologic confirmation. Two types of ultrasound contrast agents are commercially available: pure intravascular agents (such as SonoVue) and Kupffer agents (such as Sonazoid). Major guidelines recognize CEUS as a reliable imaging method for HCC diagnosis, although they differ depending on the contrast agents used. The Korean Liver Cancer Association-National Cancer Center guideline includes CEUS with either SonoVue or Sonazoid as a second-line diagnostic technique. However, Sonazoid-enhanced ultrasound is associated with several unresolved issues. This review provides a comparative overview of these contrast agents regarding pharmacokinetic features, examination protocols, diagnostic criteria for HCC, and potential applications in the HCC diagnostic algorithm.

Abstract Image

查看原文本刊更多论文

Sonazoid增强超声对肝细胞癌的无创成像诊断：特别强调2022年KLCA-NCC指南。

造影增强超声（CEUS）是一种无创成像方式，用于根据特定的成像特征诊断肝细胞癌（HCC），无需病理证实。市场上有两种类型的超声造影剂：纯血管内造影剂（如SonoVue）和库普弗造影剂（例如Sonazoid）。主要指南认为CEUS是诊断HCC的可靠成像方法，尽管它们因使用的造影剂而异。韩国癌症协会-国家癌症中心指南包括使用SonoVue或Sonazoid作为二线诊断技术的CEUS。然而，声纳增强超声与几个尚未解决的问题有关。这篇综述对这些造影剂的药代动力学特征、检查方案、HCC诊断标准以及在HCC诊断算法中的潜在应用进行了比较概述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ultrasonography Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

5.10

自引率

6.50%

发文量

审稿时长

15 weeks

期刊介绍： Ultrasonography, the official English-language journal of the Korean Society of Ultrasound in Medicine (KSUM), is an international peer-reviewed academic journal dedicated to practice, research, technology, and education dealing with medical ultrasound. It is renamed from the Journal of Korean Society of Ultrasound in Medicine in January 2014, and published four times per year: January 1, April 1, July 1, and October 1. Original articles, technical notes, topical reviews, perspectives, pictorial essays, and timely editorial materials are published in Ultrasonography covering state-of-the-art content. Ultrasonography aims to provide updated information on new diagnostic concepts and technical developments, including experimental animal studies using new equipment in addition to well-designed reviews of contemporary issues in patient care. Along with running KSUM Open, the annual international congress of KSUM, Ultrasonography also serves as a medium for cooperation among physicians and specialists from around the world who are focusing on various ultrasound technology and disease problems and relevant basic science.